Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021
October 20, 2021 at 11:58 am EDT
Share
Syngene International Limited reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was INR 6,102 million compared to INR 5,196 million a year ago. Revenue was INR 6,231 million compared to INR 5,334 million a year ago. Net income was INR 667 million compared to INR 841 million a year ago. Basic earnings per share from continuing operations was INR 1.64 compared to INR 2.12 a year ago. Diluted earnings per share from continuing operations was INR 1.63 compared to INR 2.1 a year ago.
For the six months, sales was INR 12,047 million compared to INR 9,412 million a year ago. Revenue was INR 12,299 million compared to INR 9,703 million a year ago. Net income was INR 1,440 million compared to INR 1,421 million a year ago. Basic earnings per share from continuing operations was INR 3.55 compared to INR 3.58 a year ago. Diluted earnings per share from continuing operations was INR 3.53 compared to INR 3.57 a year ago.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.